Cargando…

TAK1 regulates hepatic lipid homeostasis through SREBP

Sterol regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Morioka, Sho, Sai, Kazuhito, Omori, Emily, Ikeda, Yuka, Matsumoto, Kunihiro, Ninomiya-Tsuji, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956508/
https://www.ncbi.nlm.nih.gov/pubmed/26973245
http://dx.doi.org/10.1038/onc.2015.453
_version_ 1782444037480906752
author Morioka, Sho
Sai, Kazuhito
Omori, Emily
Ikeda, Yuka
Matsumoto, Kunihiro
Ninomiya-Tsuji, Jun
author_facet Morioka, Sho
Sai, Kazuhito
Omori, Emily
Ikeda, Yuka
Matsumoto, Kunihiro
Ninomiya-Tsuji, Jun
author_sort Morioka, Sho
collection PubMed
description Sterol regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP regulation is well studied, stimuli-dependent regulatory mechanisms are still elusive. Here we demonstrate that SREBPs are regulated by a previously uncharacterized mechanism through TGF-β activated kinase 1 (TAK1), a signaling molecule of inflammation. We found that TAK1 binds to and inhibits mature forms of SREBPs. In an in vivo setting, hepatocyte-specific Tak1 deletion upregulates liver lipid deposition and lipogenic enzymes in the mouse model. Furthermore, hepatic Tak1 deficiency causes steatosis pathologies including elevated blood triglyceride and cholesterol levels, which are established risk factors for the development of hepatocellular carcinoma (HCC) and are indeed correlated with Tak1-deficiency-induced HCC development. Pharmacological inhibition of SREBPs alleviated the steatosis and reduced the expression level of the HCC marker gene in the Tak1-deficient liver. Thus, TAK1 regulation of SREBP critically contributes to the maintenance of liver homeostasis to prevent steatosis, which is a potentially important mechanism to prevent HCC development.
format Online
Article
Text
id pubmed-4956508
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-49565082016-09-14 TAK1 regulates hepatic lipid homeostasis through SREBP Morioka, Sho Sai, Kazuhito Omori, Emily Ikeda, Yuka Matsumoto, Kunihiro Ninomiya-Tsuji, Jun Oncogene Article Sterol regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP regulation is well studied, stimuli-dependent regulatory mechanisms are still elusive. Here we demonstrate that SREBPs are regulated by a previously uncharacterized mechanism through TGF-β activated kinase 1 (TAK1), a signaling molecule of inflammation. We found that TAK1 binds to and inhibits mature forms of SREBPs. In an in vivo setting, hepatocyte-specific Tak1 deletion upregulates liver lipid deposition and lipogenic enzymes in the mouse model. Furthermore, hepatic Tak1 deficiency causes steatosis pathologies including elevated blood triglyceride and cholesterol levels, which are established risk factors for the development of hepatocellular carcinoma (HCC) and are indeed correlated with Tak1-deficiency-induced HCC development. Pharmacological inhibition of SREBPs alleviated the steatosis and reduced the expression level of the HCC marker gene in the Tak1-deficient liver. Thus, TAK1 regulation of SREBP critically contributes to the maintenance of liver homeostasis to prevent steatosis, which is a potentially important mechanism to prevent HCC development. 2016-03-14 2016-07-21 /pmc/articles/PMC4956508/ /pubmed/26973245 http://dx.doi.org/10.1038/onc.2015.453 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Morioka, Sho
Sai, Kazuhito
Omori, Emily
Ikeda, Yuka
Matsumoto, Kunihiro
Ninomiya-Tsuji, Jun
TAK1 regulates hepatic lipid homeostasis through SREBP
title TAK1 regulates hepatic lipid homeostasis through SREBP
title_full TAK1 regulates hepatic lipid homeostasis through SREBP
title_fullStr TAK1 regulates hepatic lipid homeostasis through SREBP
title_full_unstemmed TAK1 regulates hepatic lipid homeostasis through SREBP
title_short TAK1 regulates hepatic lipid homeostasis through SREBP
title_sort tak1 regulates hepatic lipid homeostasis through srebp
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956508/
https://www.ncbi.nlm.nih.gov/pubmed/26973245
http://dx.doi.org/10.1038/onc.2015.453
work_keys_str_mv AT moriokasho tak1regulateshepaticlipidhomeostasisthroughsrebp
AT saikazuhito tak1regulateshepaticlipidhomeostasisthroughsrebp
AT omoriemily tak1regulateshepaticlipidhomeostasisthroughsrebp
AT ikedayuka tak1regulateshepaticlipidhomeostasisthroughsrebp
AT matsumotokunihiro tak1regulateshepaticlipidhomeostasisthroughsrebp
AT ninomiyatsujijun tak1regulateshepaticlipidhomeostasisthroughsrebp